XPost: talk.politics.guns, alt.politics.homosexuality, alt.politics.nationalism.black
XPost: alt.hollywood
In article <t1tgu4$38pca$
128@news.freedyn.de>
<
governor.swill@gmail.com> wrote:
The queers know how to stop it. If they won't, let the fucking
degenerates die.
Infectious disease experts and public health advocates are
warning that the Biden administration has been too slow to
respond to the monkeypox outbreak and that the U.S. is at risk
of losing control of the disease.
The response to monkeypox is mirroring the worst parts of the
early days of the coronavirus pandemic, they say, with severely
limited testing and a sluggish rollout of vaccines leading to a
virus that’s spreading undetected.
“Where we have lagged is streamlining testing, making vaccines
available, streamlining access to the best therapeutics. All
three areas have been bureaucratic and slow, and that means we
haven’t contained this outbreak,” said David Harvey, executive
director of the National Coalition of STD Directors (NCSD).
Unlike COVID-19, monkeypox is not a novel virus, and the
strategies to reduce the spread are well known. Biden
administration officials said they are confident in their
approach.
“We as a global community have known about it for decades. We
know how it spreads. We have tests that help identify people who
are infected. We have vaccines that are highly effective against
it,” White House coronavirus response coordinator Ashish Jha
said during a recent briefing.
According to the Centers for Disease Control and Prevention
(CDC), there are 460 cases in 30 states, Puerto Rico and D.C.,
though experts say that number is almost certainly an
undercount, as many people who may be infected don’t yet have
access to widespread testing.
The administration is ramping up its response by expanding
testing capacity and broadening access to vaccinations, though
critics say the efforts may be coming too late.
“We’ve been sort of screaming for a month about how bad the
diagnostic situation is for monkeypox. And that really was a
clear error, preventable, and it’s very clear that this
administration has not learned lessons from early COVID,” said
James Krellenstein, co-founder of the HIV treatment advocacy
group Prep4All.
Jon Andrus, an adjunct professor of global health at George
Washington University’s Milken Institute School of Public
Health, said the U.S. is lucky that monkeypox is not as
contagious as COVID-19, or as deadly, because the public health
system is underfunded and overly fractured.
“I think we’ll continue to repeat these mistakes because that’s
been our track record. That’s been our track record. We’ve had,
what, more than five or six waves of COVID, and we seem every
time to be a little bit caught off guard,” Andrus said.
“Stopping transmission requires that we’re all reading from the
same page. We all have the same road map.”
The administration expanded testing to commercial labs in late
June, so providers will soon be able to order tests directly
from the labs where they have established relationships and can
jump through fewer hoops.
But it took more than a month for that move to happen, which
increased testing capacity from about 8,000 tests a week to
10,000 across the entire system.
Demand is also not evenly spread across the public health
laboratory networks; it is concentrated in urban areas such as
New York City, leading to backlogs and frustrated patients who
wait days for test results.
Biden administration health officials this week touted efforts
to expand testing.
“I strongly encourage all health care providers to have a high
clinical suspicion for monkeypox among their patients,” CDC
Director Rochelle Walensky said during a call with reporters.
“Patients presenting with a suspicious rash should be tested.”
Testing for monkeypox is a relatively simple process that
involves swabbing a skin lesion. Unlike with COVID-19, the CDC
already had a previously developed test, but patients were
limited to a narrow set of specific criteria in order to qualify
for testing.
“We already had testing available. We already had vaccines
available. We should have really been much more aggressive with
testing … and I think this speaks to some of the bureaucracy of
both FDA [Food and Drug Administration] and CDC,” said Celine
Gounder, an infectious disease specialist and editor-at-large
for public health at Kaiser Health News.
“Getting the commercial labs on board they could have done
sooner. Getting academic medical centers to do testing, hospital
labs to develop their own PCR tests. I mean, that’s not a very
difficult thing to do,” Gounder said.
The White House is also working to scale up its vaccination
program and announced a plan to immediately send out tens of
thousands of doses of Jynneos, the only FDA-approved vaccine
specifically for monkeypox.
More than a million doses will be made available throughout the
year. The CDC is also broadening the eligibility criteria so
individuals with confirmed monkeypox exposures and presumed
exposures can be vaccinated, rather than only those who have a
confirmed case.
But activists and experts say the administration moved too
slowly and that the updated vaccination strategy is not nearly
sufficient.
“We believe this outbreak is already out of control. So, we have
not contained it. Vaccines are not going to contain it at this
point. Because we don’t have enough. Getting them into arms is
an expensive and intense process,” said NCSD’s Harvey.
New York City and Washington, D.C., began offering the vaccines
to men who have sex with other men or may have been exposed to
the virus. But both cities ran through their supplies less than
a day after launching their local immunization initiatives. D.C.
Health had to shut access about 10 minutes after making shots
available.
There are about 56,000 Jynneos doses in the Strategic National
Stockpile that will be allocated immediately, officials said,
and the administration plans to allocate 296,000 doses over the
coming weeks.
The U.S. has tens of millions of doses of the smallpox vaccine
ACAM2000, but that shot has more dangerous and severe side
effects.
According to a spokesman for Jynneos’s Denmark-based
manufacturer Bavarian Nordic, 300,000 doses have already been
delivered or will be arriving over the next few days.
An additional 1.1 million filled doses are still being inspected
by the FDA, which should finish in the next couple weeks.
Nearly 15,000 flights delayed so far during holiday travel
weekend
Zelensky: 2,610 Ukrainian cities, towns remain under Russian
occupation
The government also owns bulk materials totaling as many as 15
million doses, but they are still frozen, and the administration
has not told the company how it wants those doses filled.
“American taxpayers spent money buying and manufacturing these
doses precisely so they can be used rapidly in the event of an
outbreak,” said Krellenstein of Prep4All.
“Here we have an outbreak, and my friends are literally being
turned away from being vaccinated because the Biden
administration can’t figure out how to get a million doses out
of a freezer in Denmark into the United States,” Krellenstein
added.
https://thehill.com/policy/healthcare/3544371-advocates-warn-us- at-risk-of-losing-control-on-monkeypox/
--- SoupGate-Win32 v1.05
* Origin: fsxNet Usenet Gateway (21:1/5)